
Virbac S.A (VIRP) | Financial Analysis & Statements
Virbac S.A. | Large-cap | Healthcare
Virbac S.A. | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.8B
Total Liabilities
805.1M
Shareholders Equity
1.0B
Debt to Equity
0.77
Cash Flow Metrics
Revenue & Profitability Trend
Virbac S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.4B | 1.2B | 1.2B | 1.1B | 934.2M |
Cost of Goods Sold | 459.8M | 437.3M | 426.2M | 363.1M | 319.9M |
Gross Profit | 937.6M | 809.6M | 790.0M | 700.9M | 614.3M |
Gross Margin % | 67.1% | 64.9% | 65.0% | 65.9% | 65.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | 203.5M | 159.6M |
Other Operating Expenses | 280.3M | 247.6M | 250.8M | 208.8M | 14.3M |
Total Operating Expenses | 280.3M | 247.6M | 250.8M | 412.2M | 174.0M |
Operating Income | 228.3M | 185.7M | 183.5M | 166.8M | 122.9M |
Operating Margin % | 16.3% | 14.9% | 15.1% | 15.7% | 13.2% |
Non-Operating Items | |||||
Interest Income | 6.4M | 8.7M | 4.8M | 2.4M | 2.0M |
Interest Expense | 11.1M | 8.9M | 3.7M | 6.0M | 10.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 207.8M | 174.2M | 176.4M | 159.1M | 173.3M |
Income Tax | 62.5M | 53.5M | 55.7M | 43.6M | 33.3M |
Effective Tax Rate % | 30.1% | 30.7% | 31.6% | 27.4% | 19.2% |
Net Income | 145.8M | 121.1M | 121.3M | 115.7M | 140.3M |
Net Margin % | 10.4% | 9.7% | 10.0% | 10.9% | 15.0% |
Key Metrics | |||||
EBITDA | 289.8M | 226.7M | 236.6M | 217.0M | 179.4M |
EPS (Basic) | €17.35 | €14.40 | €14.43 | €13.40 | €16.12 |
EPS (Diluted) | €17.34 | €14.38 | €14.42 | €13.38 | €16.12 |
Basic Shares Outstanding | 8372978 | 8421787 | 8448180 | 8442111 | 8436696 |
Diluted Shares Outstanding | 8372978 | 8421787 | 8448180 | 8442111 | 8436696 |
Income Statement Trend
Virbac S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 149.6M | 175.9M | 177.4M | 172.8M | 181.9M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 196.1M | 168.0M | 146.3M | 107.4M | 101.7M |
Inventory | 404.2M | 339.7M | 330.9M | 270.3M | 211.0M |
Other Current Assets | - | - | - | - | -1.0K |
Total Current Assets | 844.1M | 771.5M | 723.5M | 624.7M | 569.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 44.6M | 40.4M | 37.6M | 33.4M | 30.9M |
Goodwill | 804.5M | 515.9M | 444.6M | 429.8M | 414.8M |
Intangible Assets | 251.2M | 185.1M | 154.4M | 148.7M | 145.3M |
Long-term Investments | 1.4M | 43.0K | 89.0K | 137.0K | 1.0K |
Other Non-Current Assets | 4.0K | 3.0K | -1.0K | 2.0K | -2.0K |
Total Non-Current Assets | 1.0B | 684.2M | 610.1M | 576.9M | 539.7M |
Total Assets | 1.8B | 1.5B | 1.3B | 1.2B | 1.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 174.6M | 149.6M | 155.8M | 127.6M | 105.3M |
Short-term Debt | 62.7M | 54.5M | 45.0M | 51.9M | 38.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 464.6M | 399.0M | 390.6M | 370.8M | 311.7M |
Non-Current Liabilities | |||||
Long-term Debt | 244.3M | 65.6M | 45.4M | 42.6M | 77.4M |
Deferred Tax Liabilities | 57.2M | 31.6M | 25.8M | 27.9M | 30.3M |
Other Non-Current Liabilities | -1.0K | -2.0K | -1.0K | -1.0K | -1.0K |
Total Non-Current Liabilities | 340.6M | 146.8M | 103.7M | 105.6M | 142.6M |
Total Liabilities | 805.1M | 545.8M | 494.3M | 476.4M | 454.3M |
Equity | |||||
Common Stock | 10.5M | 10.6M | 10.6M | 10.6M | 10.6M |
Retained Earnings | 145.3M | 121.3M | 121.9M | 113.2M | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.0B | 909.9M | 839.3M | 725.2M | 655.2M |
Key Metrics | |||||
Total Debt | 307.0M | 120.1M | 90.4M | 94.5M | 115.4M |
Working Capital | 379.6M | 372.4M | 332.9M | 253.9M | 258.1M |
Balance Sheet Composition
Virbac S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 145.8M | 121.1M | 121.3M | 115.7M | 140.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -33.3M | -29.4M | -80.2M | -48.9M | -30.1M |
Operating Cash Flow | 118.0M | 87.6M | 45.2M | 75.0M | 110.0M |
Investing Activities | |||||
Capital Expenditures | -69.2M | -41.0M | -38.7M | -33.7M | -22.5M |
Acquisitions | -348.4M | -62.4M | 0 | -5.9M | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -417.7M | -103.4M | -38.7M | -39.6M | -22.5M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -11.1M | -11.2M | -10.6M | -6.3M | - |
Debt Issuance | 273.6M | 88.7M | 85.4M | 65.6M | 45.0M |
Debt Repayment | -89.3M | -50.5M | -96.5M | -78.0M | -373.3M |
Financing Cash Flow | 155.8M | 27.0M | -20.5M | -73.7M | -328.4M |
Free Cash Flow | 123.8M | 58.7M | 45.4M | 82.7M | 89.9M |
Net Change in Cash | -143.8M | 11.2M | -14.1M | -38.3M | -240.8M |
Cash Flow Trend
Virbac S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.67
Forward P/E
17.20
Price to Book
2.74
Price to Sales
2.05
PEG Ratio
17.20
Profitability Ratios
Profit Margin
10.40%
Operating Margin
11.52%
Return on Equity
14.93%
Return on Assets
8.66%
Financial Health
Current Ratio
1.82
Debt to Equity
29.98
Beta
0.83
Per Share Data
EPS (TTM)
€17.36
Book Value per Share
€124.56
Revenue per Share
€166.89
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
virp | 2.9B | 19.67 | 2.74 | 14.93% | 10.40% | 29.98 |
EssilorLuxottica | 123.5B | 51.90 | 3.26 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.3B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
bioMérieux S.A | 15.0B | 34.86 | 3.56 | 10.68% | 10.86% | 11.65 |
Eurofins Scientific | 12.0B | 29.67 | 3.49 | 8.68% | 6.05% | 88.06 |
Financial data is updated regularly. All figures are in the company's reporting currency.